Low-Dose Hydrocortisone Improves Cognition in Women With HIV | Infectious Disease News

Women living with HIV often experience heightened stress and mood disorders, which can significantly impact cognitive functions like verbal learning and memory. Emerging research suggests a potential avenue for improvement: low-dose hydrocortisone. A recent study, presented at the Conference on Retroviruses and Opportunistic Infections in February 2026, indicates that this readily available medication may offer cognitive benefits for this population, both acutely and over a period of weeks.

The Link Between HIV, Stress, and Cognition

The cognitive challenges experienced by women with HIV are complex and multifaceted. As Dr. Leah Rubin, a professor of neurology, psychiatry, and behavioral sciences at Johns Hopkins University, explained, “Women with HIV tend to experience high levels of trauma and chronic stress and tend to have a lot of mood anxiety and posttraumatic stress disorder, all of which are robust predictors of cognitive function, particularly as we think of learning and memory.” This connection is thought to be mediated, in part, by dysregulation of the hypothalamic pituitary adrenal (HPA) axis, the body’s central stress response system, leading to elevated cortisol levels.

Hydrocortisone, a synthetic form of cortisol, has been explored as a potential means of modulating this HPA axis activity. The rationale is that carefully calibrated, low doses could help restore balance and, improve cognitive performance. This approach isn’t about simply increasing cortisol levels, but rather about optimizing the body’s natural stress response.

Study Design and Findings

Dr. Rubin and her team conducted a two-phase clinical trial to investigate the effects of low-dose hydrocortisone in virally suppressed women with HIV who also reported experiencing stress, mood disorders, or objective cognitive impairment. The study involved 81 women with a indicate age of 55.2 years, with 81% identifying as Black.

Phase 1 was a double-blind, placebo-controlled crossover trial. Participants received either a single 10 mg dose of hydrocortisone or a placebo, and their cognitive function was assessed at 30 minutes and 4 hours post-dose. The results showed that hydrocortisone led to a significant increase in cortisol levels, peaking around 75 minutes after administration. Notably, at the 30-minute mark, the medication improved attention (P < .05). At 4 hours, improvements were observed in both attention (P < .05) and verbal learning, as measured by the Hopkins Verbal Learning Test-Revised (P = .03).

Phase 2 was a randomized, double-blind, placebo-controlled trial lasting 4 weeks. Participants were randomly assigned to receive either daily low-dose hydrocortisone or a placebo. The primary outcome measures were changes in cognitive function over time. The findings revealed that daily hydrocortisone treatment prevented the decline in attentional measures compared to the placebo group (P = .016) and improved delayed recall (P = .005). However, the effect on delayed recall wasn’t consistently observed over the entire 4-week period.

Importantly, the study found that low-dose hydrocortisone was well-tolerated, with no serious adverse events reported. This is a crucial consideration, as safety is paramount when introducing any medication, particularly in a population already managing a chronic condition like HIV. You can find more details about the study design and results in the abstract presented at the Conference on Retroviruses and Opportunistic Infections: Rubin L, et al. Abstract 112.

What Does This Mean for Women with HIV?

The study’s findings suggest that low-dose hydrocortisone holds promise as a potential intervention to improve cognitive function in women with HIV. Dr. Rubin highlighted the potential mechanisms at play, suggesting that the observed improvements may be linked to both acute pharmacological effects and longer-term genomic changes. “We saw some improvements: 30 minutes attention and concentration, 4 hours attention, verbal learning, memory — [at] 28 days, specifically verbal memory,” she stated.

However, it’s crucial to emphasize that this research is still in its early stages. Whereas the results are encouraging, they do not represent a definitive cure or treatment. Further research is needed to confirm these findings, determine the optimal dosage and duration of treatment, and identify which women with HIV are most likely to benefit. It’s also important to note that the study population was relatively small and predominantly Black, which limits the generalizability of the findings to other populations.

Understanding Cortisol and the HPA Axis

The HPA axis is a complex network of glands that regulates the body’s response to stress. When faced with a stressful situation, the hypothalamus releases corticotropin-releasing hormone (CRH), which stimulates the pituitary gland to release adrenocorticotropic hormone (ACTH). ACTH, in turn, signals the adrenal glands to produce cortisol. Cortisol plays a vital role in mobilizing energy stores, suppressing inflammation, and regulating immune function.

However, chronic stress can lead to HPA axis dysregulation, resulting in persistently elevated cortisol levels. This can have detrimental effects on cognitive function, particularly in areas like learning and memory. The hippocampus, a brain region crucial for memory formation, is particularly vulnerable to the damaging effects of chronic cortisol exposure. For more information on the HPA axis, you can visit the Endocrine Society’s website.

The Next Steps in Research and Clinical Practice

The findings from Dr. Rubin’s study warrant further investigation. Researchers are planning larger, more diverse clinical trials to validate these results and explore the long-term effects of low-dose hydrocortisone treatment. These trials will also aim to identify biomarkers that can predict which women with HIV are most likely to respond to treatment.

Currently, low-dose hydrocortisone is not a standard treatment for cognitive impairment in women with HIV. However, these findings may prompt clinicians to consider it as a potential option for carefully selected patients, particularly those with evidence of HPA axis dysregulation. It’s essential that any treatment decisions are made in consultation with a qualified healthcare professional, taking into account the individual patient’s medical history and overall health status. The National Institutes of Health provides information on ongoing HIV research, including clinical trials, at NIAID’s HIV/AIDS page.

As research progresses, a more nuanced understanding of the interplay between HIV, stress, the HPA axis, and cognitive function will emerge, paving the way for more effective interventions to improve the quality of life for women living with this condition.